Shoubridge Andrew P, Brass Amanda, Crotty Maria, Morawska Lidia, Bell Scott C, Flynn Erin, Miller Caroline, Wang Yiming, Holden Carol A, Corlis Megan, Larby Nicolas, Worley Paul, Elms Levi, Manning Sarah K, Qiao Ming, Inacio Maria C, Wesselingh Steve L, Papanicolas Lito E, Woodman Richard J, Taylor Steven L, Rogers Geraint B
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
JAMA Intern Med. 2025 Jul 28. doi: 10.1001/jamainternmed.2025.3388.
Infectious outbreaks of respiratory viruses within long-term care facilities (LTCFs) for older adults are associated with high rates of hospitalization and death. Despite evidence that airborne transmission contributes substantially to the spread of respiratory viruses within residential care for older adults, this mode of transmission has been largely unaddressed by existing infection control practices.
To determine whether germicidal UV (GUV) appliances reduce acute respiratory infection (ARI) incidence in LTCFs.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter, 2-arm, double-crossover, cluster randomized clinical trial assessed the effectiveness of GUV appliances in common spaces on the incidence of ARIs in 4 LTCFs in metropolitan and regional South Australia. LTCFs were divided into 2 equally sized zones (mean [SD] size, 44 [9] beds per zone). Within each LTCF, zones were randomized to active GUV appliances (intervention) or inactive (control) for 6 weeks, which was followed by a 2-week washout, crossover, and a further 2-week washout. Seven consecutive cycles were performed during the 110-week study period from August 31, 2021, to November 13, 2023. Data were analyzed from January 18, 2024, to December 4, 2024.
Continuous GUV appliance activity within common (non-resident room) areas for 6 weeks.
The primary outcome was the incidence rate of ARIs (per zone per cycle). A secondary analysis of long-term trends was performed based on infections per week.
Eight assessed zones across 4 LTCFs represented a total of 211 952 bed-days. Of 596 ARIs recorded across all zones, 475 (79.7%) occurred during intervention or control periods. The incidence rate in the control arm was 4.17 infections per zone per cycle (95% CI, 2.43-5.91), compared with 3.81 infections per zone per cycle (95% CI, 2.21-5.41) in the intervention arm (incidence rate ratio, 0.91; 95% CI, 0.77-1.09; P = .33). A posteriori secondary analysis with time-series autoregressive modeling showed that the control group recorded 2.61 ARIs per week (95% CI, 2.51-2.70) compared with 2.29 ARIs per week (95% CI, 2.06-2.51) in the intervention group (mean difference, 0.32; 95% CI, 0.10-0.54; P = .004).
This randomized clinical trial found that GUV light appliances in common areas of LTCFs did not reduce the incidence rate of ARIs per zone per cycle but did modestly reduce the total numbers of ARIs by the study conclusion. GUV appliances might be considered to support existing infection prevention and control practices in these settings.
Australian and New Zealand Clinical Trial Registration: ACTRN12621000567820.
在老年人长期护理机构(LTCFs)中,呼吸道病毒的传染性暴发与高住院率和死亡率相关。尽管有证据表明空气传播在老年人住宿护理机构中对呼吸道病毒传播有很大影响,但这种传播方式在现有感染控制措施中基本未得到解决。
确定杀菌紫外线(GUV)设备是否能降低长期护理机构中急性呼吸道感染(ARI)的发病率。
设计、设置和参与者:这项多中心、双臂、双交叉、整群随机临床试验评估了GUV设备在南澳大利亚大都市和地区的4个长期护理机构公共区域对急性呼吸道感染发病率的有效性。长期护理机构被分为2个大小相等的区域(平均[标准差]大小,每个区域44[9]张床位)。在每个长期护理机构内,各区域被随机分配到使用有源GUV设备(干预组)或无源设备(对照组),为期6周,随后是2周的洗脱期、交叉期,以及另外2周的洗脱期。在2021年8月31日至2023年11月13日的110周研究期间进行了7个连续周期。数据于2024年1月18日至2024年12月4日进行分析。
在公共(非居住房间)区域持续使用GUV设备6周。
主要结局是急性呼吸道感染的发病率(每个区域每个周期)。基于每周的感染情况进行了长期趋势的二次分析。
4个长期护理机构的8个评估区域共计211952个床日。在所有区域记录的596例急性呼吸道感染中,475例(79.7%)发生在干预期或对照期。对照组每个区域每个周期的发病率为4.17例感染(95%置信区间,2.43 - 5.91),干预组为每个区域每个周期3.81例感染(95%置信区间,2.21 - 5.41)(发病率比,0.91;95%置信区间,0.77 - 1.09;P = 0.33)。采用时间序列自回归模型进行的事后二次分析显示,对照组每周记录2.61例急性呼吸道感染(95%置信区间,2.51 - 2.70),干预组为每周2.29例急性呼吸道感染(95%置信区间,2.06 - 2.51)(平均差异,0.32;95%置信区间,0.10 - 0.54;P = 0.004)。
这项随机临床试验发现,长期护理机构公共区域的GUV照明设备并未降低每个区域每个周期的急性呼吸道感染发病率,但到研究结束时确实适度降低了急性呼吸道感染的总数。在这些环境中,可考虑使用GUV设备来支持现有的感染预防和控制措施。
澳大利亚和新西兰临床试验注册:ACTRN12621000567820。